Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evommune, Inc.EVMN · Entity 5539 | Chief Financial Officer | July 08, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evommune, Inc.
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 60,335 |
Reported balance
After 2026-07-08 transaction · row 1
1 source rowRow 1 · 2026-07-08 · Purchase · Acquired 1,000 · Balance 60,335 F1: The purchase by the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sales of 1,000 shares of the Issuer's common stock by the reporting person at the price of $23.42 per share on May 28, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the purchase, $10,160, representing the full amount of the profit realized in connection with the short-swing transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: The purchase by the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sales of 1,000 shares of the Issuer's common stock by the reporting person at the price of $23.42 per share on May 28, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the purchase, $10,160, representing the full amount of the profit realized in connection with the short-swing transaction.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kadmon Holdings, Inc.
Report date November 09, 2021 · Filed November 09, 2021
Section 16 reporting ended · disclosed 2021-11-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 1
1 source rowRow 1 · 2021-11-09 · Disposition to issuer · Disposed 15,420 · Balance 0 F1: Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.66 · Expires 2026-12-15 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-09 · Disposition to issuer · Disposed 45,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.64 · Expires 2027-12-08 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-09 · Disposition to issuer · Disposed 55,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2028-12-14 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-09 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.34 · Expires 2030-01-27 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-09 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.96 · Expires 2031-01-08 | Direct | 0 |
Reported balance
After 2021-11-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-09 · Disposition to issuer · Disposed 175,000 · Balance 0 F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger").
F2: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option.
F3: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 10, 2026 23:59 UTC | Evommune, Inc. EVMN · Entity 5539 | PurchaseCommon Stock | 1,000 | $13.26 | $13,260.00 |
DisclosureSEC source: 0001757072-26-000007 · primarydocument.xml · nonDerivative · entry 1 Carver Kyle · CIK 0001757072 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,335 F1 · kind: The purchase by the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sales of 1,000 shares of the Issuer's common stock by the reporting person at the price of $23.42 per share on May 28, 2026. The reporting person has agreed to pay to the Issuer upon settlement of the purchase, $10,160, representing the full amount of the profit realized in connection with the short-swing transaction. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 23:59 UTC | Evommune, Inc. EVMN · Entity 5539 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001757072-26-000005 · primarydocument.xml · derivative · entry 3 Carver Kyle · CIK 0001757072 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,731 Underlying: Common Stock · 15,000 shares Expires 2034-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026. F3 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 23:59 UTC | Evommune, Inc. EVMN · Entity 5539 | SaleCommon Stock | 18,175 | $22.84 | $415,117.00 |
DisclosureSEC source: 0001757072-26-000005 · primarydocument.xml · nonDerivative · entry 2 Carver Kyle · CIK 0001757072 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,335 F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $22.50 to $23.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 23:59 UTC | Evommune, Inc. EVMN · Entity 5539 | Exercise / conversionCommon Stock | 15,000 | $2.99 | $44,850.00 |
DisclosureSEC source: 0001757072-26-000005 · primarydocument.xml · nonDerivative · entry 1 Carver Kyle · CIK 0001757072 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2026. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 21:23 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantEmployee Stock Option (Right to Buy) · Derivative | 98,946 | $0.00 Strike: $26.77 | $0.00 |
DisclosureSEC source: 0001757072-26-000003 · primarydocument.xml · derivative · entry 1 Carver Kyle · CIK 0001757072 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,946 Underlying: Common Stock · 98,946 shares Expires 2036-04-15 F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 21:20 UTC | Evommune, Inc. EVMN · Entity 5539 | Tax withholdingCommon Stock | 13,290 | $17.84 | $237,093.60 |
DisclosureSEC source: 0001757072-25-000010 · primarydocument.xml · nonDerivative · entry 1 Carver Kyle · CIK 0001757072 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,510 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:16 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionSeries B Preferred Stock · Derivative | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001757072-25-000008 · form4-11122025_091140.xml · derivative · entry 2 Carver Kyle · CIK 0001757072 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 21:16 UTC | Evommune, Inc. EVMN · Entity 5539 | ConversionCommon Stock | 3,175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001757072-25-000008 · form4-11122025_091140.xml · nonDerivative · entry 1 Carver Kyle · CIK 0001757072 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-7.8721 basis and had no expiration date. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:15 UTC | Evommune, Inc. EVMN · Entity 5539 | GrantEmployee Stock Option (Right to Buy) · Derivative | 279,408 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001757072-25-000006 · form4-11072025_041105.xml · derivative · entry 1 Carver Kyle · CIK 0001757072 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,408 Underlying: Common Stock · 279,408 shares Expires 2035-11-04 F1 · derivative.exercise_date: One fourth (1/4) of the shares subject to the option award shall vest on November 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:36 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 175,000 | $5.54 Strike: $3.96 | $969,500.00 |
DisclosureSEC source: 0001104659-21-136396 · tm2131118-2_4seq1.xml · derivative · entry 6 Carver Kyle · CIK 0001757072 · SVP, CAO, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 175,000 shares Expires 2031-01-08 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:36 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | $5.16 Strike: $4.34 | $516,000.00 |
DisclosureSEC source: 0001104659-21-136396 · tm2131118-2_4seq1.xml · derivative · entry 5 Carver Kyle · CIK 0001757072 · SVP, CAO, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 100,000 shares Expires 2030-01-27 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:36 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | $7.03 Strike: $2.47 | $351,500.00 |
DisclosureSEC source: 0001104659-21-136396 · tm2131118-2_4seq1.xml · derivative · entry 4 Carver Kyle · CIK 0001757072 · SVP, CAO, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 50,000 shares Expires 2028-12-14 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:36 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 55,000 | $5.86 Strike: $3.64 | $322,300.00 |
DisclosureSEC source: 0001104659-21-136396 · tm2131118-2_4seq1.xml · derivative · entry 3 Carver Kyle · CIK 0001757072 · SVP, CAO, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 55,000 shares Expires 2027-12-08 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:36 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerStock Option (right to buy) · Derivative | 45,000 | $4.84 Strike: $4.66 | $217,800.00 |
DisclosureSEC source: 0001104659-21-136396 · tm2131118-2_4seq1.xml · derivative · entry 2 Carver Kyle · CIK 0001757072 · SVP, CAO, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 · 45,000 shares Expires 2026-12-15 F3 · price: Represents the payment per share of Common Stock received in exchange for the cancellation of each Option. F2 · derivative.exercise_date: In connection with the Merger, all unvested stock options ("Options") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option. Read SEC document |
| November 09, 2021 Filed Nov 9, 2021 17:36 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | Disposition to issuerCommon Stock | 15,420 | $9.50 | $146,490.00 |
DisclosureSEC source: 0001104659-21-136396 · tm2131118-2_4seq1.xml · nonDerivative · entry 1 Carver Kyle · CIK 0001757072 · SVP, CAO, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed pursuant to the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger (the "Merger"). Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 16:22 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $3.96 | $0.00 |
DisclosureSEC source: 0001593968-21-000117 · primary_01.xml · derivative · entry 1 Carver Kyle · CIK 0001757072 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common stock, par value $0.001 · 175,000 shares Expires 2031-01-08 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments over 3 years from January 8, 2021, the date of grant. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 16:28 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001593968-20-000232 · primary_01.xml · derivative · entry 1 Carver Kyle · CIK 0001757072 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common stock, par value $0.001 · 100,000 shares Expires 2030-01-27 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal annual installments over 3 years from January 27, 2020, the date of grant. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 10:27 UTC | Kadmon Holdings, Inc. KDMN · Entity 133686 | GrantOption (right to buy) · Derivative | 50,000 | $2.47 Strike: $2.47 | $123,500.00 |
DisclosureSEC source: 0001593968-18-001606 · primary_01.xml · derivative · entry 1 Carver Kyle · CIK 0001757072 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock, par value $0.001 · 50,000 shares Expires 2028-12-14 F1 · balance_after: Only represents derivative securities of this class. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.